Dr. Tobias Bonifert, Head of Vector Technology, CEVEC Pharmaceuticals GmbH
Articles
Reduction of Product-related Impurities during Production of recombinant Adeno-Associated Viruses
Dr. Michelle Hussong, Head of Molecular Biology - Technology and Assay Development, CEVEC Pharmaceuticals GmbH;Dr. Tobias Bonifert, Head of Vector Technology, CEVEC Pharmaceuticals GmbH;Prof. Dr. Nico Scheer, Senior Consultant Business Development, CEVEC Pharmaceuticals GmbH, Professor in Molecular Biology at FH Aachen, University of Applied Sciences, Germany
June 9th 2022Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: October 28th 2024 | Updated: November 22nd 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 15th 2024 | Updated: November 22nd 2024
Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs
Published: October 28th 2024 | Updated: November 22nd 2024
Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems
Published: October 22nd 2024 | Updated: November 22nd 2024
Optimizing cGMP Facility Design Space with a Hybrid Approach
